Skip to main content
Top
Published in: BMC Infectious Diseases 1/2020

Open Access 01-12-2020 | Amphotericin B | Research article

The clinical characteristics and outcome of cryptococcal meningitis with AIDS in a tertiary hospital in China: an observational cohort study

Authors: Liang Wu, Jiang Xiao, Yangzi Song, Guiju Gao, Hongxin Zhao

Published in: BMC Infectious Diseases | Issue 1/2020

Login to get access

Abstract

Background

Despite the profound impact of antiretroviral therapy in the control of AIDS mortality, central nervous system opportunistic infections remains a significant burden in AIDS patients. This retrospective study aims to elucidate the clinical characteristics, outcome and risk factors of cryptococcal meningitis (CM) poor prognosis in AIDS patients from a tertiary hospital in China.

Methods

Clinical data from 128 patients admitted in Beijing Ditan Hospital, Capital Medical University from November 2008 to November 2017 was collected. The cohort was stratified based on treatment outcome (effective 79%, and ineffective 21%), and Multivariate Logistic regression analysis used to identify risk factors of poor disease prognosis.

Results

Age, incidence of cerebral infarction, the proportion of consciousness disorder, and fasting plasma glucose was higher in the ineffective treatment group than the effective treatment group. The duration of treatment in the induction period of the ineffective group was significantly shorter than that of the effective group. Multivariate Logistic regression analysis indicated that the occurrence of cerebral hernia and consciousness disorder were risk factors for the prognosis of AIDS patients with CM infection, while the duration of treatment in the induction period was a indicative of a better prognosis in AIDS with CM infection complications. Finally, shunt decompression therapy correlated with a better disease outcome.

Conclusions

This retrospective study exposes the main risk factors associated with worse disease prognosis in AIDS patients with CM infection complications.
Literature
1.
go back to reference Bowen LN, Smith B, Reich D, et al. HIV-associated opportunistic CNS infections: pathophysiology, diagnosis and treatment. Nat Rev Neurol. 2016;12(11):662–74.CrossRef Bowen LN, Smith B, Reich D, et al. HIV-associated opportunistic CNS infections: pathophysiology, diagnosis and treatment. Nat Rev Neurol. 2016;12(11):662–74.CrossRef
2.
go back to reference McKenney J, Bauman S, Neary B, et al. Prevalence, correlates, and outcomes of cryptococcal antigen positivity among patients with AIDS, United States, 1986–2012. Clin Infect Dis. 2015;60(6):959–65.CrossRef McKenney J, Bauman S, Neary B, et al. Prevalence, correlates, and outcomes of cryptococcal antigen positivity among patients with AIDS, United States, 1986–2012. Clin Infect Dis. 2015;60(6):959–65.CrossRef
3.
go back to reference Yang H, Yin F, Xiao T, et al. A correlation analysis between clinical manifestations, therapeutic strategies, and the prognosis of children with cryptococcal meningitis in China. Int J Infect Dis. 2020;95:241–5.CrossRef Yang H, Yin F, Xiao T, et al. A correlation analysis between clinical manifestations, therapeutic strategies, and the prognosis of children with cryptococcal meningitis in China. Int J Infect Dis. 2020;95:241–5.CrossRef
4.
go back to reference Bicanic T, Brouwer AE, Meintjes G, et al. Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS (London, England). 2009;23(6):701–6. Bicanic T, Brouwer AE, Meintjes G, et al. Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS (London, England). 2009;23(6):701–6.
5.
go back to reference Lu YQ, Huang XJ, Wu YS, et al. A retrospective study on prognostic factors of cryptococcal meningitis in 203 patients with acquired immunodeficiency syndrome. Chin J Neuromed. 2018;17(4):397–401 (in Chinese with English abstract). Lu YQ, Huang XJ, Wu YS, et al. A retrospective study on prognostic factors of cryptococcal meningitis in 203 patients with acquired immunodeficiency syndrome. Chin J Neuromed. 2018;17(4):397–401 (in Chinese with English abstract).
6.
go back to reference Xu L, Tao R, Wu J, et al. Short-course rather than low-dose amphotericin B may exert potential influence on mortality in Cryptococcal meningitis patients treated with amphotericin B plus Flucytosine alone or in combination with fluconazole. Front Microbiol. 2019;10:2082.CrossRef Xu L, Tao R, Wu J, et al. Short-course rather than low-dose amphotericin B may exert potential influence on mortality in Cryptococcal meningitis patients treated with amphotericin B plus Flucytosine alone or in combination with fluconazole. Front Microbiol. 2019;10:2082.CrossRef
7.
go back to reference Chinese center for disease control and prevention. Chinese guidelines for diagnosis and treatment of HIV/AIDS (2018). Zhonghua Nei Ke Za Zhi. 2018;57(12):867–84. Chinese center for disease control and prevention. Chinese guidelines for diagnosis and treatment of HIV/AIDS (2018). Zhonghua Nei Ke Za Zhi. 2018;57(12):867–84.
8.
go back to reference Chinese association of infectious diseases. Expert consensus on the diagnosis and treatment of cryptococcal meningitis. Zhonghua Nei Ke Za Zhi. 2018;57(5):317–23. Chinese association of infectious diseases. Expert consensus on the diagnosis and treatment of cryptococcal meningitis. Zhonghua Nei Ke Za Zhi. 2018;57(5):317–23.
9.
go back to reference Jarvis JN, Harrison TS. HIV-associated cryptococcal meningitis. AIDS (London, England). 2007;21(16):2119–29.CrossRef Jarvis JN, Harrison TS. HIV-associated cryptococcal meningitis. AIDS (London, England). 2007;21(16):2119–29.CrossRef
10.
go back to reference Jarvis JN, Bicanic T, Loyse A, et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes. Clin Infect Dis. 2014;58(5):736–45.CrossRef Jarvis JN, Bicanic T, Loyse A, et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes. Clin Infect Dis. 2014;58(5):736–45.CrossRef
11.
go back to reference Ogundeji AO, Albertyn J, Pohl CH, et al. Method for identification of Cryptococcus neoformans and Cryptococcus gattii useful in resource-limited settings. J Clin Pathol. 2016;69(4):352–7.CrossRef Ogundeji AO, Albertyn J, Pohl CH, et al. Method for identification of Cryptococcus neoformans and Cryptococcus gattii useful in resource-limited settings. J Clin Pathol. 2016;69(4):352–7.CrossRef
12.
go back to reference Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010;50(3):291–322.CrossRef Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010;50(3):291–322.CrossRef
13.
go back to reference Njei B, Kongnyuy EJ, Kumar S, et al. Optimal timing for antiretroviral therapy initiation in patients with HIV infection and concurrent cryptococcal meningitis. Cochrane Database Syst Rev. 2013;2:D9012. Njei B, Kongnyuy EJ, Kumar S, et al. Optimal timing for antiretroviral therapy initiation in patients with HIV infection and concurrent cryptococcal meningitis. Cochrane Database Syst Rev. 2013;2:D9012.
14.
go back to reference Wu X, Shen Y. Management of human immunodeficiency virus-associated cryptococcal meningitis: current status and future directions. Mycoses. 2019;62(10):874–82.CrossRef Wu X, Shen Y. Management of human immunodeficiency virus-associated cryptococcal meningitis: current status and future directions. Mycoses. 2019;62(10):874–82.CrossRef
15.
go back to reference Tenforde MW, Shapiro AE, Rouse B, et al. Treatment for HIV-associated cryptococcal meningitis. Cochrane Database Syst Rev. 2018;7:D5647. Tenforde MW, Shapiro AE, Rouse B, et al. Treatment for HIV-associated cryptococcal meningitis. Cochrane Database Syst Rev. 2018;7:D5647.
16.
go back to reference Yan Y, Mai L, Xu WX, et al. The 10-year clinical analysis of cryptococcal meningitis treated with flueonazole and flucytosine. Chin J Infect Dis. 2012;30(5):293–6 (in Chinese with English abstract). Yan Y, Mai L, Xu WX, et al. The 10-year clinical analysis of cryptococcal meningitis treated with flueonazole and flucytosine. Chin J Infect Dis. 2012;30(5):293–6 (in Chinese with English abstract).
17.
go back to reference Molloy SF, Kanyama C, Heyderman RS, et al. Antifungal combinations for treatment of Cryptococcal meningitis in Africa. N Engl J Med. 2018;378(11):1004–17.CrossRef Molloy SF, Kanyama C, Heyderman RS, et al. Antifungal combinations for treatment of Cryptococcal meningitis in Africa. N Engl J Med. 2018;378(11):1004–17.CrossRef
18.
go back to reference World Health Organization. Guidelines for the diagnosis, prevention and Management of Cryptococcal Disease in HIV-infected adults, adolescents and children: supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: WHO; 2018. World Health Organization. Guidelines for the diagnosis, prevention and Management of Cryptococcal Disease in HIV-infected adults, adolescents and children: supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: WHO; 2018.
19.
go back to reference Shimoda Y, Ohtomo S, Arai H, et al. Subarachnoid small vein occlusion due to inflammatory fibrosis-a possible mechanism for cerebellar infarction in cryptococcal meningoencephalitis: a case report. BMC Neurol. 2017;17(1):157.CrossRef Shimoda Y, Ohtomo S, Arai H, et al. Subarachnoid small vein occlusion due to inflammatory fibrosis-a possible mechanism for cerebellar infarction in cryptococcal meningoencephalitis: a case report. BMC Neurol. 2017;17(1):157.CrossRef
20.
go back to reference Lofgren S, Hullsiek KH, Morawski BM, et al. Differences in immunologic factors among patients presenting with altered mental status during Cryptococcal meningitis. J Infect Dis. 2017;215(5):693–7.CrossRef Lofgren S, Hullsiek KH, Morawski BM, et al. Differences in immunologic factors among patients presenting with altered mental status during Cryptococcal meningitis. J Infect Dis. 2017;215(5):693–7.CrossRef
21.
go back to reference Liu L, Zhang R, Tang Y, et al. The use of ventriculoperitoneal shunts for uncontrollable intracranial hypertension in patients with HIV-associated cryptococcal meningitis with or without hydrocephalus. Biosci Trends. 2014;8(6):327–32.CrossRef Liu L, Zhang R, Tang Y, et al. The use of ventriculoperitoneal shunts for uncontrollable intracranial hypertension in patients with HIV-associated cryptococcal meningitis with or without hydrocephalus. Biosci Trends. 2014;8(6):327–32.CrossRef
22.
go back to reference Cherian J, Atmar RL, Gopinath SP. Shunting in cryptococcal meningitis. J Neurosurg. 2016;125(1):177–86.CrossRef Cherian J, Atmar RL, Gopinath SP. Shunting in cryptococcal meningitis. J Neurosurg. 2016;125(1):177–86.CrossRef
23.
go back to reference Baddley JW, Thompson GR, Riley KO, et al. Factors associated with Ventriculoperitoneal shunt placement in patients with Cryptococcal meningitis. Open Forum Infect Dis. 2019;6(6):z241.CrossRef Baddley JW, Thompson GR, Riley KO, et al. Factors associated with Ventriculoperitoneal shunt placement in patients with Cryptococcal meningitis. Open Forum Infect Dis. 2019;6(6):z241.CrossRef
Metadata
Title
The clinical characteristics and outcome of cryptococcal meningitis with AIDS in a tertiary hospital in China: an observational cohort study
Authors
Liang Wu
Jiang Xiao
Yangzi Song
Guiju Gao
Hongxin Zhao
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2020
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-020-05661-9

Other articles of this Issue 1/2020

BMC Infectious Diseases 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.